Tempus AI Faces Consolidated Lawsuits Over Genetic Data Sharing
Multiple class-action lawsuits over genetic data use were consolidated against Tempus AI on April 15, 2026.
Why it matters: These suits put a spotlight on privacy and compliance risks when genetic data changes hands in major healthcare AI deals. Legal teams in regulated sectors face new challenges in navigating evolving statutes and patient consent expectations.
- Tempus AI acquired Ambry Genetics for $600M in February 2025.
- Lawsuits allege improper use and sharing of genetic data with over 70 pharma companies.
- The agreements generated about $1.1B in value with firms like AstraZeneca and Pfizer.
- Plaintiffs invoke genetic privacy statutes in seven states, arguing genetic information can't be de-identified.
Tempus AI, which bought Ambry Genetics for $600 million in February 2025, is under legal fire after using the newly acquired genetic database to power its AI models and enter lucrative partnerships.
- The database covers genetic information from hundreds of thousands of individuals originally collected for medical testing purposes with confidentiality expectations, according to attorney James Fessenden of Fisher Phillips.
- Tempus AI shared this sensitive data with over 70 pharmaceutical and biotech partners, including industry leaders AstraZeneca, Bristol Myers Squibb, Pfizer, and GlaxoSmithKline, generating agreements worth roughly $1.1 billion.
On April 15, 2026, multiple class-action lawsuits were consolidated as Farrier et al v. Tempus AI, Inc. in the U.S. District Court for the Northern District of Illinois. The plaintiffs cite violations of the Illinois Genetic Information Privacy Act and similar statutes in California, Florida, Georgia, Michigan, New York, and West Virginia (full details here).
- The core claim: genetic data, as an inherently unique biomarker, can never truly be de-identified.
The outcome of this litigation could reshape legal and compliance practices for AI-driven healthcare companies as they navigate increasingly strict data privacy regimes. Read more industry analysis from the National Law Review.
By the numbers:
- $600M — Cost for Tempus AI to acquire Ambry Genetics
- $1.1B — Total value of Tempus AI's agreements sharing the genetic data
- 7 — States where genetic privacy statutes are cited in the lawsuits